Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-10

Study Completion Date

2018-10-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

\- To assess the safety of SAR341402 and NovoLog® when used in external insulin pumps in terms of the number of patients with infusion set occlusions.

Secondary Objectives:

* To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of unexplained hyperglycemia.
* To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of:
* Intervals for infusion set changes.
* Number of patients with insulin pump for "non-delivery" alarm.
* Patient observation of infusion set occlusion.
* Adverse events and serious adverse events.
* Number of patients with hypoglycemic events \[according to ADA (American Diabetes Association) Workgroup on hypoglycemia\].

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

NCT02612844

Diabetes Diabetes Mellitus, Type 1

COMPLETED PHASE1

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

NCT04409587

Type1 Diabetes Mellitus

COMPLETED PHASE4

A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

NCT02623478

Diabetes Mellitus, Type 1

WITHDRAWN PHASE1

A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump

NCT03056456

Diabetes Mellitus, Type 1

COMPLETED PHASE1

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

NCT07305805

Diabetes Mellitus, Type 1

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study duration for each patient will be approximately 10 weeks, including a 2-week screening period, 2 treatment periods of 4 weeks each, and 1-day post-treatment safety follow-up period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAR341402/NovoLog

SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.

Group Type EXPERIMENTAL

Insulin aspart SAR341402

Intervention Type DRUG

Pharmaceutical form: Solution

Route of administration: Subcutaneous

NovoLog/SAR341402

Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.

Group Type EXPERIMENTAL

Insulin aspart

Intervention Type DRUG

Pharmaceutical form: Solution

Route of administration: Subcutaneous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insulin aspart SAR341402

Pharmaceutical form: Solution

Route of administration: Subcutaneous

Intervention Type DRUG

Insulin aspart

Pharmaceutical form: Solution

Route of administration: Subcutaneous

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients with Type 1 diabetes mellitus (T1DM).
* Age greater than or equal to 18 at the screening visit.
* Diabetes diagnosed at least 12 months before screening visit.
* At least 1 year of insulin treatment with at least 6 months of CSII (Continuous Subcutaneous Insulin Infusion) treatment with an external insulin pump.
* Demonstration of successful use of insulin pump and performing of a minimum of 4 blood glucose checks per day during screening.
* Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for T1DM patients.
* Signed written informed consent.

Exclusion Criteria

* Hemoglobin A1c (HbA1c) ≥8.5% at screening.
* Diabetes other than T1DM.
* History of infection at the infusion site within 3 months prior to the screening visit (Visit 1).
* Use of oral glucose-lowering agents or any injectable glucose-lowering agents other than insulin during the 3 months before screening visit.
* Hospitalization for recurrent diabetic ketoacidosis (DKA) in the last 6 months before screening visit.
* History of severe hypoglycemia requiring emergency room admission or hospitalization in the last 6 months before screening visit.
* Hypoglycemic unawareness as judged by the Investigator in the last 6 months before the screening visit.
* Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study.
* Known history of illegal drug or alcohol abuse within 6 months prior to the time of screening.
* Use of investigational drug(s) within 3 months or 5 half-lives, whichever is longer, prior to the screening visit.
* Patients who had previously received SAR341402 in any other clinical trial.
* Any contraindication to the use of NovoLog® as defined in the national product labels; history of hypersensitivity to NovoLog® or to any of the excipients.
* Pregnancy and lactation.
* If female, pregnancy \[defined as positive β-HCG (Human Chorionic Gonadotropin) in blood or in urine\], breast-feeding.
* Patient is an employee or relative of an employee of the sponsor.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No